MA55209A - Procédés de traitement de l'amylose al - Google Patents

Procédés de traitement de l'amylose al

Info

Publication number
MA55209A
MA55209A MA055209A MA55209A MA55209A MA 55209 A MA55209 A MA 55209A MA 055209 A MA055209 A MA 055209A MA 55209 A MA55209 A MA 55209A MA 55209 A MA55209 A MA 55209A
Authority
MA
Morocco
Prior art keywords
amylodis
treating
methods
Prior art date
Application number
MA055209A
Other languages
English (en)
Inventor
Carol Karp
Gene Kinney
Radhika Tripuraneni
Wagner Zago
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MA55209A publication Critical patent/MA55209A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
MA055209A 2019-03-05 2020-03-05 Procédés de traitement de l'amylose al MA55209A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02

Publications (1)

Publication Number Publication Date
MA55209A true MA55209A (fr) 2022-01-12

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055209A MA55209A (fr) 2019-03-05 2020-03-05 Procédés de traitement de l'amylose al

Country Status (17)

Country Link
US (3) US11692024B2 (fr)
EP (2) EP3934689B1 (fr)
JP (2) JP7619953B2 (fr)
KR (1) KR20220019656A (fr)
CN (1) CN113811332A (fr)
AU (1) AU2020231081A1 (fr)
BR (1) BR112021017550A2 (fr)
CA (1) CA3132780A1 (fr)
CL (1) CL2021002318A1 (fr)
FR (1) FR3111560B1 (fr)
IL (1) IL286040A (fr)
JO (1) JOP20210245A1 (fr)
MA (1) MA55209A (fr)
MX (1) MX2021010665A (fr)
PH (1) PH12021552135A1 (fr)
SG (1) SG11202109645QA (fr)
WO (1) WO2020178638A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7619953B2 (ja) * 2019-03-05 2025-01-22 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法
JP2023541191A (ja) * 2020-09-14 2023-09-28 ケーラム バイオサイエンシーズ， インコーポレイテッド アミロイドーシスを治療する方法
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
CN118749002A (zh) * 2022-01-11 2024-10-08 普罗塞纳生物科学有限公司 治疗al淀粉样变性的方法
AR132344A1 (es) * 2023-04-10 2025-06-18 Medimmune Llc Optimización de los dominios de unión al antígeno cd3
WO2025170969A1 (fr) * 2024-02-06 2025-08-14 Prothena Biosciences Limited Méthodes de traitement de l'amylose al

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP3312196B1 (fr) 2005-03-23 2019-07-17 Genmab A/S Anticorps dirigés contre cd38 pour le traitement du myélome multiple
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
EP3613774A1 (fr) 2010-06-09 2020-02-26 Genmab A/S Anticorps diriges contre le cd38 humain
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
CN104023748B (zh) 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
HRP20220979T8 (hr) * 2016-06-30 2023-02-03 Prothena Biosciences Limited Sastavi za liječenje amiloidoze
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CN113924099A (zh) 2019-02-12 2022-01-11 普罗塞纳生物科学有限公司 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性
JP7619953B2 (ja) * 2019-03-05 2025-01-22 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Also Published As

Publication number Publication date
JOP20210245A1 (ar) 2023-01-30
EP4582446A2 (fr) 2025-07-09
AU2020231081A1 (en) 2021-09-30
BR112021017550A2 (pt) 2021-11-09
SG11202109645QA (en) 2021-10-28
PH12021552135A1 (en) 2022-08-31
FR3111560A1 (fr) 2021-12-24
CA3132780A1 (fr) 2020-09-10
IL286040A (en) 2021-10-31
FR3111560B1 (fr) 2024-03-22
CL2021002318A1 (es) 2022-05-06
JP7619953B2 (ja) 2025-01-22
EP3934689A1 (fr) 2022-01-12
US12240894B2 (en) 2025-03-04
US20250188159A1 (en) 2025-06-12
KR20220019656A (ko) 2022-02-17
JP2025063135A (ja) 2025-04-15
MX2021010665A (es) 2021-12-10
US20200308260A1 (en) 2020-10-01
EP4582446A3 (fr) 2025-08-13
WO2020178638A1 (fr) 2020-09-10
US11692024B2 (en) 2023-07-04
JP2022522889A (ja) 2022-04-20
CN113811332A (zh) 2021-12-17
US20230331831A1 (en) 2023-10-19
EP3934689B1 (fr) 2025-04-23

Similar Documents

Publication Publication Date Title
MA55209A (fr) Procédés de traitement de l'amylose al
EP3976595A4 (fr) Composés de 1-oxo-isoindoline-5-carboxamide substitués, compositions de ceux-ci, et procédés de traitement associés
EP4288441A4 (fr) Procédés de traitement de l'ataxie spinocérébelleuse de type 3
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP4025256A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP3618807A4 (fr) Compositions et procédés de prévention et de traitement de perte d'audition
MA55087A (fr) Compositions et procédés de traitement de laminopathies
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3914235A4 (fr) Procédés de traitement de la dépendance
EP3389657A4 (fr) Procédés de traitement de l'hyperalgésie
MA55515A (fr) Procédés de traitement de la dystrophie musculaire avec casimersen
EP3969456A4 (fr) Procédés de traitement d'un trouble médié par mk2
EP4017924A4 (fr) Compositions et procédés de traitement de surface
EP3775171A4 (fr) Procédés de traitement d'un cancer résiduel minimal
EP3873525A4 (fr) Compositions et procédés de traitement d'une lésion cérébrale
EP3522900A4 (fr) Composés et procédés de diagnostic et de traitement d'infections virales
EP3801510A4 (fr) Procédés de traitement de dystrophies musculaires
EP3830196A4 (fr) Compositions et procédés de traitement de surface
MA47437A (fr) Procédés de traitement d'infections fongiques
EP3980540A4 (fr) Méthodes de traitement d'une déficience en alpha-1 antitrypsine (aatd)
EP4021858A4 (fr) Traitement d'azoles
EP4041312A4 (fr) Procédés de traitement d'un trouble oculaire